NLRP3 and diabetic kidney disease: Similarly, Astragaloside IV (AS-IV) ameliorates renal function and podocyte injury in db/db mice by inhibiting the TXNIP-NLRP3-GSDMD axis, exerting anti-pyroptotic effects and attenuating DKD progression (171).